Ryker Michiel Kiel, DO | |
111 S 5th St, Douglas, WY 82633-2434 | |
(307) 358-2122 | |
Not Available |
Full Name | Ryker Michiel Kiel |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 111 S 5th St, Douglas, Wyoming |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528450327 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 5101023618 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ryker Michiel Kiel, DO 1 Fairway Dr, Douglas, WY 82633-9515 Ph: () - | Ryker Michiel Kiel, DO 111 S 5th St, Douglas, WY 82633-2434 Ph: (307) 358-2122 |
News Archive
A Lancet World Report examines the details of the Canadian government's strategy for the G8 maternal and child health initiative and reactions from global health leaders and politicians to the plan, including the announcement during a meeting of G8 leaders Halifax, Nova Scotia, that the initiative would not support abortion.
The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers.
With cold and flu season around the corner, consumers will soon begin to purchase medicines such as cough syrup, throat lozenges, and nasal sprays to help get relief from symptoms such as fever, coughs, congestion, and more. Many of the medicines used to treat these cold and flu symptoms can contain common drug ingredients such as acetaminophen.
Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for the use of menadione to prevent and treat skin rash in patients taking biologic and small molecule epidermal growth factor receptor inhibitors, such as Erbitux® and Tarceva®, for anti-cancer therapy.
The WHO and FDA approve drugs to treat malaria, tuberculosis and other diseases in low- and middle-income countries, but "some of the manufacturers, predominantly Chinese and Indian firms, may be knowingly producing" poor quality medicines, according to "the conclusion of my research teams' studies, published this week in the journal Research and Reports in Tropical Medicine," Roger Bate, resident scholar with the American Enterprise Institute and lead author of the studies, writes in a Washington Post opinion piece.
› Verified 7 days ago